Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01919099 · ClinicalTrials.gov registry record

Study of the Complications Associated With Certain Stem Cell Transplants

A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
100
Enrollment target

NCT01919099 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 100 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01919099 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
100 participants
Enrollment target

Study Summary

Background: \- The National Institutes of Health (NIH) performs up to 100 allogenic stem cell transplants (allo-HSCT) each year. Many studies already look at different problems that can follow a transplant. But there are many types of transplants, diseases, responses, and treatments. An organized study of this information could help researchers learn more about how often transplant complications occur and what problems they cause. It could also lead to ideas for future research. This study will focus on complications thought to be the most significant. Objectives: \- To gather information on the complications that may occur after an allo-HSCT. Eligibility: \- People over 2 years of age currently enrolled in an allo-HSCT study at NIH. Design: * Visits for this study will be scheduled along with primary study visits. The number of visits will depend on the primary study schedule. * At each visit, participants will answer questions and take physical exams. * The same questions and physical exams will continue for as long as they are in the primary study. * In between visits, researchers might call participants to discuss their health. They may also discuss the cases with the primary study doctors and other doctors. Primary transplant study doctors will make treatment decisions. * When participation in the primary transplant study ends, participation in this study will also end.

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2013-07-31
Est. Completion 2017-08-24

What the Registry Record Tells You About NCT01919099

The ClinicalTrials.gov registry entry for NCT01919099 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT01919099 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01919099 about?

NCT01919099 is a clinical study titled "Study of the Complications Associated With Certain Stem Cell Transplants". Background: \- The National Institutes of Health (NIH) performs up to 100 allogenic stem cell transplants (allo-HSCT) each year. Many studies already look at different problems that can follow a transplant. But there are many types of transplants, diseases, responses, and treatments. An organized s...

What is the current status of trial NCT01919099?

This trial is currently completed. The enrollment target is 100 participants. The study started on 2013-07-31. Estimated completion is 2017-08-24.

Who is sponsoring clinical trial NCT01919099?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.